Monday, February 28, 2022

Ocugen (OCGN)
Pipeline Progress Updated With Fourth Quarter Financial Report

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Summary.  Ocugen reported a net loss of $14.6 million or $(0.07) per share for 4Q21, bringing FY21 loss to $58.4 million or $(0.30) per share. The company also gave updates on recent developments for its development programs. Cash at December 31, 2021 was $95.1 million, excluding proceeds of an offering completed in late February 2022.


Covaxin Is Progressing Through FDA and Heath Canada.  The FDA lifted the Clinical Hold on the IND application for the Phase 2/3 clinical trial, allowing the bridging study to continue. The Emergency Use Authorization (EUA) application submitted in November 2022 has been supplemented with safety data and studies showing neutralization of the Delta and Omicron variants …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.